Pharming Group’s (PHAR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a research report released on Tuesday,Benzinga reports. The firm currently has a $37.00 price target on the stock.

A number of other research analysts also recently weighed in on the company. Jefferies Financial Group assumed coverage on Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price on the stock. Oppenheimer cut their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, October 28th.

Pharming Group Price Performance

Shares of PHAR opened at $8.80 on Tuesday. The firm has a fifty day simple moving average of $8.28 and a two-hundred day simple moving average of $8.13. The firm has a market cap of $596.90 million, a PE ratio of -33.85 and a beta of 0.05. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. Pharming Group has a 1-year low of $6.65 and a 1-year high of $13.20.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in shares of Pharming Group (NASDAQ:PHAR) by 75.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 41,110 shares of the company’s stock after acquiring an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.